GlassScriptPhysician profile
Ranjeet Singh
NPI 1588914345
$1,119.04
in general payments reported to CMS, 2019-2025
14 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $141 · 2021: $45.17 · 2022: $133 · 2024: $135 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239 · Education: $7.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.12 |
| Education | $7.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $251.15 | 2019-2022 | |
| Amgen INC. | $212.85 | 2019-2025 | Krystexxa, Tavneos |
| Nxstage Medical, INC. | $119.37 | 2024 | |
| Akebia Therapeutics INC | $94.32 | 2019-2020 | |
| Vifor Pharma, INC. | $92.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $77.73 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $48.81 | 2021-2024 | Ultomiris |
| Mallinckrodt Enterprises LLC | $42.32 | 2019 | |
| Daiichi Sankyo INC. | $35.47 | 2019 | |
| Travere Therapeutics, INC. | $33.30 | 2025 | Filspari |
| Glaxosmithkline, LLC. | $32.44 | 2021 | |
| Mallinckrodt Hospital Products INC. | $32.08 | 2020 | |
| Alnylam Pharmaceuticals INC. | $23.93 | 2022 | |
| Horizon Therapeutics Plc | $23.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.